688505.SHG Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Market cap
- CNY 7.57B
- P/E
- -
- P/B
- 3.33x
- ROE
- -7.4%
- Dividend yield
- 0.41%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 688505.SHG undervalued?
Graham numberThe Graham number of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd yet.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People'…
Full company profileShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd financial statements
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 622M | 498M | 742M | 1.03B | 834M | 1.14B | 1.03B | 851M | 709M | 686M |
| Gross Profit | 575M | 443M | 670M | 952M | 768M | 1.06B | 945M | 777M | 646M | 686M |
| Operating Income | 155M | 76.0M | 93.0M | 247M | 173M | 217M | 133M | 97.1M | 2.39M | -155M |
| EBITDA | 184M | 118M | 150M | 304M | 232M | 271M | 207M | 153M | 59.6M | -102M |
| Net Income | 139M | 75.3M | 112M | 227M | 165M | 213M | 138M | 109M | 39.7M | -157M |
| EPS | 0.15 | 0.08 | 0.12 | 0.25 | 0.17 | 0.20 | 0.13 | 0.11 | 0.04 | -0.15 |
| Balance Sheet | ||||||||||
| Total Assets | 1.12B | 1.15B | 1.46B | 1.56B | 2.50B | 2.78B | 2.98B | 2.88B | 2.59B | 2.39B |
| Total Liabilities | 248M | 253M | 466M | 632M | 492M | 592M | 723M | 518M | 281M | 274M |
| Shareholders' Equity | 844M | 872M | 982M | 932M | 2.01B | 2.19B | 2.26B | 2.36B | 2.30B | 2.12B |
| Cash & Short-term Investments | 511M | 468M | 588M | 577M | 1.40B | 1.21B | 1.32B | 1.20B | 1.06B | 1.15B |
| Total Debt | 120M | 140M | 150M | 155M | 19.7M | 31.3M | 125M | 17.3M | 20.5M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 141M | 42.7M | 174M | 269M | 113M | 269M | 165M | 71.0M | -14.8M | 141M |
| Capital Expenditure | 46.8M | 60.9M | 37.8M | 40.4M | 42.4M | 120M | 87.3M | 99.0M | 42.7M | 32.4M |
| Free Cash Flow | 93.8M | -18.2M | 136M | 229M | 70.6M | 149M | 78.0M | -28.0M | -57.4M | 109M |
| Ratios | ||||||||||
| ROE | 16.4% | 8.6% | 11.4% | 24.4% | 8.2% | 9.7% | 6.1% | 4.6% | 1.7% | -7.4% |
| ROA | 12.4% | 6.6% | 7.7% | 14.5% | 6.6% | 7.7% | 4.6% | 3.8% | 1.5% | -6.6% |
| Net Profit Margin | 22.3% | 15.1% | 15.1% | 22.1% | 19.7% | 18.7% | 13.4% | 12.8% | 5.6% | -23.0% |
| Debt to Equity | 0.14x | 0.16x | 0.15x | 0.17x | 0.01x | 0.01x | 0.06x | 0.01x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.41%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 18, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 31.1M | 0.03 | - |
| 2024 | CNY 93.3M | 0.09 | 234.8% |
| 2023 | CNY 76.2M | 0.07 | 70.1% |
| 2022 | CNY 72.0M | 0.07 | 52.2% |
| 2021 | CNY 52.2M | 0.05 | 24.4% |
| 2020 | CNY 64.6M | 0.07 | 39.2% |
| 2019 | CNY 64.6M | 0.07 | 28.4% |
| 2018 | 27.7M | 0.03 | 24.7% |
| 2017 | CNY 46.2M | 0.05 | 61.3% |
| 2016 | 28.0M | 0.03 | 20.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Insiders 60.25%
- Institutions 0.29%
- Public & others 39.46%
- Shares outstanding 703M
- Free float 341M
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd company profile
- Company name
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Ticker
- 688505.SHG
- ISIN
- CNE100004BN8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 876
- Fiscal year end
- December
- Address
- Zhangjiang Hi-Tech Park, Shanghai, China, 201210
- Phone
- 86 21 5895 3355
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd management
9- Mr. Da Jun ZhaoCo-Founder & Executive Chairman · born 1970
- Ms. Xue Yan ACCA, CIA, CICPA, FCCA, HKICPABoard Secretary, CFO, GM & Executive Director · born 1982
- Ms. Dai Qing YuDeputy General Manager · born 1973
- Mr. Yu ChenDeputy General Manager · born 1974
- Wen ZhangAccounting Supervisor
- Mr. Luo Chun WangCore Technical Personnel · born 1970
- Mr. Jian Ping JiangCore Technical Personnel · born 1970
- Mr. Wen Bo ZhangCore Technical Personnel · born 1967
- Ms. Ji Ning TaoCore Technical Personnel · born 1972